Ativan
Generic name: Lorazepam
Brand names: Ativan
Nursing Mothers
Lorazepam has been detected in human breast milk; therefore, it should not be administered to breast-feeding women, unless the expected benefit to the woman outweighs the potential risk to the infant.
Sedation and inability to suckle have occurred in neonates of lactating mothers taking benzodiazepines. Infants of lactating mothers should be observed for pharmacological effects (including sedation and irritability).
What side effects may occur
Side effects cannot be anticipated. If any develop or change in intensity, inform your doctor as soon as possible. Only your doctor can determine if it is safe for you to continue taking Ativan.
If you experience any side effects, it will usually be at the beginning of your treatment; they will probably disappear as you continue to take the drug, or if your dosage is reduced.
Precaution
Esophageal dilation occurred in rats treated with lorazepam for more than one year at 6 mg/kg/day. The no-effect dose was 1.25 mg/kg/day (approximately 6 times the maximum human therapeutic dose of 10 mg per day). The effect was reversible only when the treatment was withdrawn within two months of first observation of the phenomenon. The clinical significance of this is unknown. However, use of lorazepam for prolonged periods and in geriatric patients requires caution, and there should be frequent monitoring for symptoms of upper G.I. disease.
Safety and effectiveness of Ativan (lorazepam) in children of less than 12 years have not been established.
Recommended dosage
The usual recommended dosage is a total of 2 to 6 milligrams per day divided into smaller doses. The largest dose should be taken at bedtime. The daily dose may vary from 1 to 10 milligrams.
Anxiety
The usual starting dose is a total of 2 to 3 milligrams per day taken in 2 or 3 smaller doses.
Insomnia Due to Anxiety
A single daily dose of 2 to 4 milligrams may be taken, usually at bedtime.
The plasma levels
The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to six months.
Studies comparing young and elderly subjects have shown that advancing age does not have a significant effect on the pharma-cokinetics of lorazepam. However, in one study involving single intravenous doses of 1.5 to 3 mg of Ativan Injection, mean total body clearance of lorazepam decreased by 20% in 15 elderly subjects of 60 to 84 years of age compared to that in 15 younger subjects of 19 to 38 years of age.
